Support for Your Early-Phase Gene Therapy Program

At Altasciences, we are committed to advancing gene therapies with precision and efficiency. In addition to hundreds of pre-screened AAV nonhuman primates (NHPs) available for gene therapy programs and decades of bioanalytical, nonclinical, and clinical expertise―we’ve compiled a comprehensive list of resources below:

A Comprehensive Guide to Gene Therapy and Improving AAV Efficiency

Learn more about our track record, expertise in navigating regulatory requirements, and how we ensure the safety and efficacy of AAV-based therapies (three case studies included).

In-House AAV Pre-Screening

Detailed information on our in-house AAV pre-screening methods for removing nonhuman primates from toxicology studies if they have antibodies against AAV8 serotypes. It covers two main assays: total antibody screening (TAb) and neutralizing antibody screening (NAb).

Expert Insights on Cell and Gene Therapy Development

This scientific journal reviews considerations for nonclinical cell and gene therapy development, including expert approaches to mitigate complex challenges, improve study efficiency, and maximize translational opportunities to first-in-human trials.

Altasciences’ Biomarkers by Indication

Our expertise in biomarker analysis supports critical go/no-go decision making by providing insight into a drug’s efficacy, safety, and mechanism of action. Assessed early in the drug development process, biomarker assays can validate targets and identify potential toxicity.

Ready to get your gene therapy development program started? Speak with one of our experts.

Our Sacramento Team is Ready to Support Your Next Gene Therapy NHP Study

With over 31,000 square feet of space and 20 animal rooms, our state-of-the-art preclinical facility in Sacramento, California, is equipped to take on your discovery and PK/PD research needs in nonhuman primates (NHPs).

With a large population of NHPs that are pre-screened for adeno-associated viruses (AAVs), we’re ready to get started on your studies immediately.

Why wait? Speak with one of our experts today to get your project started right away!

Related resources you may be interested in:

• eBook: Nonclinical Studies in Cell and Gene Therapy
• Webinar: Nonclinical AAV Gene Therapy Development
• Video: The Evolving Landscape of Gene Therapy Research

Unmatched Expertise at Your Fingertips

Looking for the perfect partner for your nonclinical ophthalmology studies? Check out Altasciences’ preclinical facility in Scranton, Pennsylvania. With nearly 20 years of experience in ocular research and a full-time, on-site ACVO board-certified veterinary ophthalmologist overseeing every study, you can rest assured that your studies will run efficiently and with attention to detail.

Altasciences’ ocular studies target therapeutic agents across various diseases and conditions, such as age-related macular degeneration, diabetic retinopathy, glaucoma, uveitis, corneal disorders, and many more. Our specialists use different formulations and routes of administration, including topical, subconjunctival, intracameral, intravitreal, and subretinal, to allow for optimal drug delivery and absorption in the target structure of the eye.

We look forward to hosting you at our Scranton facility soon. Speak with one of our experts today to start your study!

Related resources you may be interested in:

• Video: Scranton Facility Virtual Tour
• Podcast: Nonclinical Considerations When Developing an Ophthalmic Drug
• eBook: Safety Testing of Ophthalmic Products
• Webinar: Gene and Cell Therapy: Enhanced CNS and Ocular Delivery in Nonhuman Primates
• Webinar: Ocular Imaging Followed by Microscopic Analysis of Focal Chorioretinal Defects in Dutch-Belted Rabbits

Streamlined Processes. Faster Approval.

In this new video, we share how our integrated teams’ combined expertise in clinical trials and manufacturing simplify the drug development process, empowering you to bring innovative therapies to market faster and, ultimately, improve patient outcomes.

Watch now to learn how our cohesive approach minimizes delays, reduces costs, and enhances collaboration.

Start watching!

Looking for drug development and manufacturing services? Speak with one of our experts today.

Related resources that may interest you:

• Webpage: Pharmaceutical Contract Manufacturing Services
• eBook: Advantages of Conducting Early-Phase Clinical Research in Canada
• Webinar: Overcoming Challenges in Manufacturing for Clinical Trials

Groundbreaking Research Data You Can Use

Catch up on the latest insights! Our experts’ posters from the 45th Annual ACT Meeting are now available online:

• Leveraging Nonclinical Safety Evaluation Findings to Expedite Next-Generation Glucagon-Like Peptide-1 Receptor Agonists Development for Metabolic Disorders and Beyond presented by Dr. Yafei Chen, Senior Research Fellow


• Immunomodulatory Approaches in Preclinical Gene Therapy Studies presented by Dr. Nirmala Chinnappareddy, Scientist/Study Director


• Intravenous Sampling and Administration Using Instech Vascular Access Buttons™ in Rodents: Pathology Findings Related to Indwelling Vascular Catheter presented by John F. MacMaster, Scientist/Study Director


• Intra-Cerebroventricular (ICV) Route in Mice for Administration of Gene Therapy Products presented by Julie Forget, Senior Director, Safety Assessment


• Lipid Nanoparticles: A Comprehensive Assessment of Liver Enzymes, Clinical Presentation, and Immunopathology Markers in Nonhuman Primates presented by Dr. Gabriela Campoy, Scientist/Study Director


• An Examination of the Effects of Body Temperature on QT Interval in Non-Naïve Telemetered Göttingen Minipigs presented by Miri K Pannu, Associate Scientific Director

Want to learn more about our comprehensive preclinical research services? Speak with one of our experts.

SUBMIT INQUIRY

Related resources you may be interested in:

• eBook: Nonclinical Studies in Cell and Gene Therapy
• Webinar: Best Practices to Reduce Animal Use in Toxicology Studies
• Webpage: The Use of Miniature Swine in Preclinical Studies

Altasciences Supports Metsera in Their Early Stage Clinical Trials for Obesity

Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company, with nonclinical and early-stage clinical trials. This support includes a recent Phase I/II trial of MET-097i: an ultra-long-acting injectable amylin analog and fully biased GLP-1 receptor agonist.

In a trial conducted at our clinic, Metsera reported positive topline results. This study enabled Metsera to initiate a randomized 16-week Phase II trial of MET-097i, which could offer potential new treatment options for those affected by obesity. We also further supported Metsera with our proactive drug development solution, providing nonclinical, bioanalysis, CRO, and program management services for several other therapeutic candidates.

Altasciences Upholds Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services

A trusted drug development research partner for over 30 years, Altasciences remains committed to providing world-class bioanalytical services in support of the preclinical and clinical studies conducted at our cutting-edge facilities, as well as extensive standalone solutions to meet your diverse needs.

Our flexible bioanalytical services from discovery to Phase IV empower clients across every phase of research.

Let's Promote Your Project!

Interested in a custom press release, written by our experts, to feature the great research we do together? Email us to get started!

You may also be interested in:

• The Altascientist Issue No.42: Managing the Complexities of Glucagon-Like Peptide-1 Receptor Agonist Drug Development
• The Altascientist Issue No.41: Immunomodulation Assessments for Clinical Trials: Sophisticated Bioanalytical Approaches to Support Complex Modalities
• Case Study: GLP-1 RA: Overcoming Known Pharmacological Effects
• Case Study: GLP-1 RA: Rapid Clinical Phase I Study Execution
• Blog: 4 Essential Topics to Cover in Your First CRO Meeting
• Press Releases: View More

As GLP-1 drugs reshape the market, understanding their potential risks, applications, and economic effects is crucial for professionals in the pharmaceutical and healthcare industries.

Join Altasciences’ webinar to discover future trends and potential breakthroughs.

Speak with one of our experts to discuss your drug development program.

You may also be interested in these resources

• Scientific Journals: Managing the Complexities of GLP-1 Drug Development
• Fact Sheet: Metabolic Disorders Clinical Trials
• Case Study: Randomized Cross Over Efficacy Study Metabolic Disorder